Active — Not RecruitingNot Applicable

acTBS Treatment for Inpatient Subjects With Suicidality

United States40 participantsStarted 2020-01-01

Plain-language summary

This is a pilot study to analyze the benefit of accelerated continuous Transcranial magnetic stimulation for inpatient subjects suffering with suicidal ideation. This study will enroll 40 inpatient subjects recruited from the Resnick Neuropsychiatric hospital. Subjects will be blinded and randomized to active or sham TMS treatment and will receive up to 5 assigned treatments per day. Subjects will also be asked to complete mood surveys throughout their participation. Participation in this study will last 7-10 days depending on scheduling.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Inpatients admitted for "suicidality" with a documented diagnosis of MDD
✓. Between the ages of 18 and 65
✓. No safety concerns endorsed on the Screening 13-item Questionnaire for rTMS Candidates16
✓. Have not received single-pulse or repetitive-TMS in the past, i.e. considered "TMS naïve".

What they're measuring

Change in Suicidal Ideation Attributes Scales (SI-DAS)

Timeframe: Baseline to Final visit

Change in Inventory of Depressive Symptom (Self-report)

Timeframe: Baseline to final visit

Trial details

NCT IDNCT04197765

SponsorUniversity of California, Los Angeles

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-01-01

View on ClinicalTrials.gov More Suicidality trials